Research Analysts Offer Predictions for Celldex Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:CLDX)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at Leerink Partnrs upped their Q2 2024 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a research note issued on Monday, May 6th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical company will post earnings per share of ($0.51) for the quarter, up from their previous forecast of ($0.69). The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.85) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ Q3 2024 earnings at ($0.54) EPS, Q4 2024 earnings at ($0.62) EPS, FY2024 earnings at ($2.22) EPS, FY2025 earnings at ($2.84) EPS, FY2026 earnings at ($3.70) EPS, FY2027 earnings at ($3.56) EPS and FY2028 earnings at $1.53 EPS.

Other analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Friday, March 22nd. Finally, Guggenheim lifted their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $66.00.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX opened at $41.21 on Thursday. The business’s 50 day moving average price is $41.71 and its 200-day moving average price is $37.03. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -14.16 and a beta of 1.60. Celldex Therapeutics has a fifty-two week low of $22.11 and a fifty-two week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. The company had revenue of $4.13 million during the quarter, compared to analyst estimates of $1.20 million.

Hedge Funds Weigh In On Celldex Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. ProShare Advisors LLC lifted its stake in shares of Celldex Therapeutics by 45.2% during the first quarter. ProShare Advisors LLC now owns 11,166 shares of the biopharmaceutical company’s stock worth $469,000 after buying an additional 3,476 shares during the period. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics during the 1st quarter worth about $147,000. Swiss National Bank grew its stake in Celldex Therapeutics by 17.8% during the 1st quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock valued at $4,797,000 after purchasing an additional 17,300 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Celldex Therapeutics by 3,327.0% in the first quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock valued at $28,879,000 after purchasing an additional 668,002 shares during the period. Finally, Capstone Investment Advisors LLC raised its stake in shares of Celldex Therapeutics by 50.7% in the first quarter. Capstone Investment Advisors LLC now owns 19,065 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 6,412 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.